Tags

Type your tag names separated by a space and hit enter

Clinical experience with pentoxifylline in occlusive cerebrovascular disorders.
Angiology 1977; 28(5):340-5A

Abstract

Pentoxifylline--3,7-dimethyl-1(5-oxo-hexyl) xanthine--a new vasodilator compound, was tried in 28 cases of occlusive cerebrovascular disease. A similar group of 24 patients were given xanthinol nicotinate. Although in terms of degree of improvement there was no significant difference in the two treatment groups, improvement was earlier in the group treated with pentoxifylline. No significant side effects were observed with any of the two drugs used in the present study.

Authors

No affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

869291

Citation

Sen, S, and A Chakravarty. "Clinical Experience With Pentoxifylline in Occlusive Cerebrovascular Disorders." Angiology, vol. 28, no. 5, 1977, pp. 340-5.
Sen S, Chakravarty A. Clinical experience with pentoxifylline in occlusive cerebrovascular disorders. Angiology. 1977;28(5):340-5.
Sen, S., & Chakravarty, A. (1977). Clinical experience with pentoxifylline in occlusive cerebrovascular disorders. Angiology, 28(5), pp. 340-5.
Sen S, Chakravarty A. Clinical Experience With Pentoxifylline in Occlusive Cerebrovascular Disorders. Angiology. 1977;28(5):340-5. PubMed PMID: 869291.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Clinical experience with pentoxifylline in occlusive cerebrovascular disorders. AU - Sen,S, AU - Chakravarty,A, PY - 1977/5/1/pubmed PY - 1977/5/1/medline PY - 1977/5/1/entrez SP - 340 EP - 5 JF - Angiology JO - Angiology VL - 28 IS - 5 N2 - Pentoxifylline--3,7-dimethyl-1(5-oxo-hexyl) xanthine--a new vasodilator compound, was tried in 28 cases of occlusive cerebrovascular disease. A similar group of 24 patients were given xanthinol nicotinate. Although in terms of degree of improvement there was no significant difference in the two treatment groups, improvement was earlier in the group treated with pentoxifylline. No significant side effects were observed with any of the two drugs used in the present study. SN - 0003-3197 UR - https://www.unboundmedicine.com/medline/citation/869291/Clinical_experience_with_pentoxifylline_in_occlusive_cerebrovascular_disorders_ L2 - http://journals.sagepub.com/doi/full/10.1177/000331977702800505?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -